ClinicalTrials.gg
CompletedNCT01443650Updated Jun 28, 2013

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

A Phase 1 interventional study of alirocumab SAR236553 (REGN727) in Hypercholesterolemia, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-28.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
33rd of 43
36 · median 107
Started
2011
with 6 others
Phase 1
9 of 43
none open now
Registered
5th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 33rd largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 1, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

Injection Site Tolerability

Secondary Objectives:

  • To assess the safety profile of alirocumab SAR236553 (REGN727)
  • To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
Read the detailed description

Total duration for each subject (not including screening) will be approximately 85 days.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum LDL-C levels >100 mg/dL.

Exclusion criteria

Exclusion criteria:

  • Subjects indicated for the use of statins according to criteria in Adult Treatment Program (ATP) III Guidelines, as updated in 2004.
  • Initiation of a new diet or major change to a previous diet within 4 weeks prior to Screening. Subjects must be willing to maintain a consistent diet for the duration of the study.
  • Use of a medication or nutraceutical in order to alter serum lipids within 4 weeks prior to screening, including but not limited to statins, cholesterol absorption inhibitors, fibrates, niacin, bile acid resins, or red yeast rice.
  • Fasting serum triglycerides >200 mg/dL measured after an 8-12 hour fast.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    alirocumab SAR236553 (REGN727) (Formulation A x 1)

    A single subcutaneous injection of Formulation A

    Drug: alirocumab SAR236553 (REGN727)

  • Experimental
    alirocumab SAR236553 (REGN727) (Formulation B x 1)

    A single subcutaneous injection of Formulation B

    Drug: alirocumab SAR236553 (REGN727)

  • Experimental
    alirocumab SAR236553 (REGN727) (Formulation A x 2)

    2 single subcutaneous injections of Formulation A

    Drug: alirocumab SAR236553 (REGN727)

Interventions

06

What researchers measure

Primary outcomes

  1. Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)

    Time frame: 15 days

  2. Erythema at injection site by measuring diameter and qualitative assessment

    Time frame: 15 days

  3. Edema at injection site by measuring diameter and qualitative assessment

    Time frame: 15 days

Secondary outcomes

  1. Assessment of PK parameter - time to maximum concentration (tmax)

    Time frame: Up to 85 days

  2. Pharmacodynamics: Change in LDL-C from baseline

    Time frame: Up to 85 days

  3. Number of participants with Adverse Events

    Time frame: Up to 85 days

  4. Assessment of PK parameter - maximum concentration (Cmax)

    Time frame: Up to 85 days

  5. Assessment of PK parameter - area under curve (AUC)

    Time frame: Up to 85 days

  6. Assessment of PK parameter - area under curve versus time curve (AUC0-D29)

    Time frame: Zero to Day 29

  7. Assessment of PK parameter - plasma concentration on Day 29 (C D29)

    Time frame: Day 29

  8. Assessment of PK parameter - terminal elimination half-life (t1/2z)

    Time frame: Up to 85 days

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2011
First posted
Sep 30, 2011
Start
Jul 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
Jun 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01443650
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Jul 2011
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Jun 28, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion